These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 10383127)
1. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Wang J; Saunthararajah Y; Redner RL; Liu JM Cancer Res; 1999 Jun; 59(12):2766-9. PubMed ID: 10383127 [TBL] [Abstract][Full Text] [Related]
2. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO. Fliegauf M; Stock M; Berg T; Lübbert M Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901 [TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins. Moldenhauer A; Frank RC; Pinilla-Ibarz J; Holland G; Boccuni P; Scheinberg DA; Salama A; Seeger K; Moore MA; Nimer SD J Leukoc Biol; 2004 Sep; 76(3):623-33. PubMed ID: 15197237 [TBL] [Abstract][Full Text] [Related]
4. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1. Frank RC; Sun X; Berguido FJ; Jakubowiak A; Nimer SD Oncogene; 1999 Mar; 18(9):1701-10. PubMed ID: 10208431 [TBL] [Abstract][Full Text] [Related]
5. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia. Meyers S; Lenny N; Sun W; Hiebert SW Oncogene; 1996 Jul; 13(2):303-12. PubMed ID: 8710369 [TBL] [Abstract][Full Text] [Related]
6. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1. Tabe Y; Jin L; Contractor R; Gold D; Ruvolo P; Radke S; Xu Y; Tsutusmi-Ishii Y; Miyake K; Miyake N; Kondo S; Ohsaka A; Nagaoka I; Andreeff M; Konopleva M Cell Death Differ; 2007 Aug; 14(8):1443-56. PubMed ID: 17464329 [TBL] [Abstract][Full Text] [Related]
8. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Klisovic MI; Maghraby EA; Parthun MR; Guimond M; Sklenar AR; Whitman SP; Chan KK; Murphy T; Anon J; Archer KJ; Rush LJ; Plass C; Grever MR; Byrd JC; Marcucci G Leukemia; 2003 Feb; 17(2):350-8. PubMed ID: 12592335 [TBL] [Abstract][Full Text] [Related]
9. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia. Linggi B; Müller-Tidow C; van de Locht L; Hu M; Nip J; Serve H; Berdel WE; van der Reijden B; Quelle DE; Rowley JD; Cleveland J; Jansen JH; Pandolfi PP; Hiebert SW Nat Med; 2002 Jul; 8(7):743-50. PubMed ID: 12091906 [TBL] [Abstract][Full Text] [Related]
10. The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner. Elsässer A; Franzen M; Kohlmann A; Weisser M; Schnittger S; Schoch C; Reddy VA; Burel S; Zhang DE; Ueffing M; Tenen DG; Hiddemann W; Behre G Oncogene; 2003 Aug; 22(36):5646-57. PubMed ID: 12944913 [TBL] [Abstract][Full Text] [Related]
11. A hematopoietic-specific transmembrane protein, Art-1, is possibly regulated by AML1. Harada Y; Harada H; Downing JR; Kimura A Biochem Biophys Res Commun; 2001 Jun; 284(3):714-22. PubMed ID: 11396961 [TBL] [Abstract][Full Text] [Related]
12. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. Berg T; Guo Y; Abdelkarim M; Fliegauf M; Lübbert M Leuk Res; 2007 Apr; 31(4):497-506. PubMed ID: 17056112 [TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein. Yang G; Thompson MA; Brandt SJ; Hiebert SW Oncogene; 2007 Jan; 26(1):91-101. PubMed ID: 16799637 [TBL] [Abstract][Full Text] [Related]
14. Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells. Barbetti V; Gozzini A; Rovida E; Morandi A; Spinelli E; Fossati G; Mascagni P; Lübbert M; Dello Sbarba P; Santini V Oncogene; 2008 Mar; 27(12):1767-78. PubMed ID: 17891169 [TBL] [Abstract][Full Text] [Related]
16. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Yergeau DA; Hetherington CJ; Wang Q; Zhang P; Sharpe AH; Binder M; Marín-Padilla M; Tenen DG; Speck NA; Zhang DE Nat Genet; 1997 Mar; 15(3):303-6. PubMed ID: 9054947 [TBL] [Abstract][Full Text] [Related]
17. Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed Bcl-2. Kohzaki H; Ito K; Huang G; Wee HJ; Murakami Y; Ito Y Oncogene; 1999 Jul; 18(28):4055-62. PubMed ID: 10435586 [TBL] [Abstract][Full Text] [Related]
18. Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repression. Claus R; Fliegauf M; Stock M; Duque JA; Kolanczyk M; Lübbert M J Leukoc Biol; 2006 Dec; 80(6):1462-72. PubMed ID: 17000900 [TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Ferrara FF; Fazi F; Bianchini A; Padula F; Gelmetti V; Minucci S; Mancini M; Pelicci PG; Lo Coco F; Nervi C Cancer Res; 2001 Jan; 61(1):2-7. PubMed ID: 11196162 [TBL] [Abstract][Full Text] [Related]
20. [Effect of phenylbutyrate, a histone deacetylase inhibitor, on differentiation and apoptosis of Kasumi-1 cells]. Hao CL; Tang KJ; Tian Z; Xing HY; Wang M; Wang JX Zhonghua Xue Ye Xue Za Zhi; 2003 May; 24(5):241-4. PubMed ID: 12859874 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]